Financial Performance - The total operating revenue for 2025 reached RMB 47.86 million, representing a year-on-year increase of 89.80%[5] - The net profit attributable to the parent company was a loss of RMB 157.94 million, an increase in loss of RMB 6.58 million compared to the previous year[5] - The earnings per share remained at RMB -0.56, indicating no change from the previous year[3] Assets and Equity - The total assets at the end of the reporting period were RMB 3,701.98 million, an increase of 248.65% from the beginning of the period[5] - The equity attributable to the parent company increased to RMB 2,896.98 million, a growth of 381.75% compared to the beginning of the period[5] - The net asset per share attributable to the parent company increased to RMB 8.10, a rise of 261.61%[3] - The company experienced a significant increase in total assets and equity due to the funds raised from its initial public offering[6] Product Development - The new product Aofumin® was launched in July 2025, contributing significantly to the revenue growth[5] - The company maintained a high level of R&D investment to support ongoing research and development projects[5] Financial Reporting - Investors are advised to note that the financial data presented is preliminary and unaudited, with final figures to be disclosed in the annual report[7]
禾元生物(688765) - 2025 Q4 - 年度业绩